Most of the studies have shown that patients with HER2-low BC tend to have a better and superior DFS and OS compared to HER2-0 in the HR-positive group, whereas they have not concluded any significant improvement in the prognosis between HER2-low and HER2-zero in the HR-negative population [54]. Here, ERBB2 is linked to breast cancer.